These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 8133049)

  • 1. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
    J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R; Weiner GJ
    J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI; Nelson H; Thibault C
    J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C; Dean PA; Nelson H
    Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
    J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
    J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice.
    Smans KA; Hoylaerts MF; Narisawa S; Millán JL; De Broe ME
    Cancer Res; 1995 Oct; 55(19):4383-90. PubMed ID: 7671251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
    J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
    J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
    Tutt AL; Reid R; Wilkins BS; Glennie MJ
    J Immunol; 1995 Sep; 155(6):2960-71. PubMed ID: 7673714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.